Press Releases

Biomind Labs Inc., a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) for the treatment of mental health disorders and beyond, is pleased to announce that its second Phase II clinical trial on N, N-dimethyltryptamine (“DMT”) for treatment-resistant depression has been approved by the Brazilian Institutional Review Board (the “IRB”). “Just a few months ago, we announced th

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced a cooperative agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR), the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the U.S. Army Contracting

Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, and Aetion, a global real-world evidence (RWE) technology and analytics provider, today announced a strategic partnership to develop a validated predictive model to identify patients with rapidly progressing mild cognitive impairment (MCI) and Alzheimer’s disease. There are approximately 13.5 million adults over the age of 65 living with MCI in the United S

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines in response to the Complete Response Letter (CRL) issued by the FDA in October 2021. The resubmission follows the company’s Type A meeting in December 202

Veristat, a scientific-minded global clinical research organization (CRO), announced today the expansion and strengthening of its service capabilities by acquiring SFL (Solutions for Life Sciences). With headquarters in Basel, Switzerland and several European affiliates, SFL brings unique capabilities and a highly credentialed team to support a growing number of biotech, pharmaceutical and medtech companies. Led by Founder and CEO Shayesteh Fürst-Ladani, the SFL team has longst

AIM ImmunoTech Inc.  an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the sale of its facility located in New Brunswick, New Jersey for a purchase price of $3.9 million. Thomas Equels, Chief Executive Officer of AIM commented, “Our priorities are focused on positioning the Company to advan

Astellas Pharma Inc. today announced topline results from the Phase 3 SKYLIGHT 4™ clinical trial investigating the long-term safety of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause (VMS) which will support future regulatory filing submissions. VMS, characterized by hot flashes (also called hot flushes) and/or night sweats, are common symptoms of menopause.1,2 SKYLIG

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the launch of its expanded suite of proteomics platforms that provide pharmaceutical and diagnostics customers with deep biological insights across the entire R&D pipeline, from early stage discovery to clinical settings. Biognosys has been offering a large variety of mass spectrometry-based proteomics contract research services for more than a decade. By organizing an

BeiGene , a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BRUKINSA® (zanubrutinib) has been approved by Health Canada for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy. “We are pleased that BRUKINSA is now approved in its third indication in Canada, R/R MZL, and this terrific milestone was made possible by the parti

Civica, Inc., announced plans to manufacture and distribute insulins that, once approved, will be available to people with diabetes at significantly lower prices than insulins currently on the market. The availability of affordable insulins will benefit people with diabetes who have been forced to choose between life sustaining medicines and living expenses, particularly those uninsured or underinsured who often pay the most out of pocket for their medications. Civica, along with Ci